Cancer Vaccines
Reports outline cancer vaccines study results from Austin Hospital
Published in Vaccine Weekly, May 13th, 2009
According to a study from Melbourne, Australia, "NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant, which generated strong humoral and T-cell - mediated immune responses and seemed to reduce the risk of disease relapse in patients with fully resected melanoma."
"This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma. Delayed-type hypersensitivity responses, circulating NY-ESO-1 - specific CD4(+)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-05-13)
More Articles from Vaccine Weekly
- Emory University
Flu vaccine given in microneedle skin patches proves effective in mice - Advaxis, Inc.
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health - Dengue Fever
Research from L. Lazo and colleagues has provided new data on dengue fever - Gene Therapy
Findings from P. Veron et al in gene therapy reported - Gene Therapy
New gene therapy study findings reported from T.H. Wang and co-authors - Gene Therapy
Research from G.P. Li and co-researchers yields new findings on gene therapy - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
